111 related articles for article (PubMed ID: 29733868)
1. Investigation of belinostat-induced genomic instability by molecular cytogenetic analysis and pathway-focused gene expression profiling.
Attia SM; Al-Hamamah MA; Alotaibi MR; Harisa GI; Attia MM; Ahmad SF; Ansari MA; Nadeem A; Bakheet SA
Toxicol Appl Pharmacol; 2018 Jul; 350():43-51. PubMed ID: 29733868
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS
J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane Averts Idarubicin-Evoked Genomic Damage by Regulating Gene Expression Profiling Associated With the DNA Damage-Signaling Pathway in BALB/c Mice.
Attia SM; Alshahrani AY; Al-Hamamah MA; Attia MM; Saquib Q; Ahmad SF; Ansari MA; Nadeem A; Bakheet SA
Toxicol Sci; 2017 Nov; 160(1):161-172. PubMed ID: 28973540
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human UDP-glucuronosyltransferase enzyme by belinostat: Implications for drug-drug interactions.
Wang X; Wang Z; Wang Z; Chen X; Yin H; Jiang L; Cao J; Liu Y
Toxicol Lett; 2021 Mar; 338():51-57. PubMed ID: 33290829
[TBL] [Abstract][Full Text] [Related]
5. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
Wang LZ; Ramírez J; Yeo W; Chan MY; Thuya WL; Lau JY; Wan SC; Wong AL; Zee YK; Lim R; Lee SC; Ho PC; Lee HS; Chan A; Ansher S; Ratain MJ; Goh BC
PLoS One; 2013; 8(1):e54522. PubMed ID: 23382909
[TBL] [Abstract][Full Text] [Related]
6. Belinostat for the treatment of peripheral T-cell lymphomas.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
[TBL] [Abstract][Full Text] [Related]
7. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
[TBL] [Abstract][Full Text] [Related]
8. Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.
Gurbani SS; Yoon Y; Weinberg BD; Salgado E; Press RH; Cordova JS; Ramesh KK; Liang Z; Velazquez Vega J; Voloschin A; Olson JJ; Schreibmann E; Shim H; Shu HG
Tomography; 2019 Mar; 5(1):53-60. PubMed ID: 30854442
[TBL] [Abstract][Full Text] [Related]
9. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
Qian X; Ara G; Mills E; LaRochelle WJ; Lichenstein HS; Jeffers M
Int J Cancer; 2008 Mar; 122(6):1400-10. PubMed ID: 18027850
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.
Chowdhury S; Howell GM; Teggart CA; Chowdhury A; Person JJ; Bowers DM; Brattain MG
J Biol Chem; 2011 Sep; 286(35):30937-30948. PubMed ID: 21757750
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Odenike O; Halpern A; Godley LA; Madzo J; Karrison T; Green M; Fulton N; Mattison RJ; Yee KW; Bennett M; Koval G; Malnassy G; Larson RA; Ratain MJ; Stock W
Invest New Drugs; 2015 Apr; 33(2):371-9. PubMed ID: 25483416
[TBL] [Abstract][Full Text] [Related]
12. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
13. Belinostat: clinical applications in solid tumors and lymphoma.
Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
[TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
[TBL] [Abstract][Full Text] [Related]
15. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
Wang L; Chan CEL; Wong AL; Wong FC; Lim SW; Chinnathambi A; Alharbi SA; Lee LS; Soo R; Yong WP; Lee SC; Ho PC; Sethi G; Goh BC
Oncotarget; 2017 Jun; 8(25):41572-41581. PubMed ID: 28157715
[TBL] [Abstract][Full Text] [Related]
16. CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Han XL; Du J; Zheng YD; Dai JJ; Lin SW; Zhang BY; Zhong FB; Lin ZG; Jiang SQ; Wei W; Fang ZY
Biomed Res Int; 2021; 2021():5089371. PubMed ID: 33959656
[TBL] [Abstract][Full Text] [Related]
17. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J
J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932
[TBL] [Abstract][Full Text] [Related]
18. [Study on the immune functions of dendritic cells regulated by histone deacetylase inhibitor Belinostat].
Jia WH; Mao H; Chen WR; Yue XT; Wei XX; Li DP; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):41-46. PubMed ID: 29551032
[No Abstract] [Full Text] [Related]
19. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.
Bailey H; McPherson JP; Bailey EB; Werner TL; Gupta S; Batten J; Reddy G; Bhat G; Sharma S; Agarwal N
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1059-1071. PubMed ID: 27744565
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
